The global apoptosis assay market is forecast to rise from USD 6.51 billion in 2025 to USD 7.07 billion in 2026 and reach USD 10.66 billion by 2031, representing an 8.57% compound annual growth rate over 2026-2031. ResearchAndMarkets said demand is being driven by higher rates of cancer, autoimmune disorders and other chronic diseases, broader use of apoptosis-modulating therapeutics, and growing investment in cell-based research, precision medicine and high-throughput screening. Assay kits led the market with a 52.48% revenue share in 2025, while flow cytometry accounted for 39.10% of detection technology revenue; reagents and consumables and spectrophotometry are projected to post the fastest growth at 9.54% and 9.98% CAGR, respectively. North America held 47.42% of 2025 revenue, while Asia-Pacific is expected to expand the fastest at 9.91% through 2031. The report also flags U.S. and European regulatory requirements and the high cost of advanced instruments as constraints on adoption.